Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

The Treatment of Depression in Patients with Heart Failure
  • Home
  • /
  • The Treatment of Depression in Patients with Heart Failure
  1. Home /
  2. Archives /
  3. Vol. 66 (2024) /
  4. Health Sciences

The Treatment of Depression in Patients with Heart Failure

Authors

  • Dominika Bachurska Faculty of Medicine, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland https://orcid.org/0009-0008-4298-2301
  • Jakub Marek 2nd Department of Clinical Radiology, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland https://orcid.org/0009-0001-6203-6282
  • Oliwia Grygorczuk Faculty of Medicine, Medical University of Lodz, al. Tadeusza Kościuszki 4, 90-419 Łódź, Poland https://orcid.org/0000-0003-3089-4546
  • Zuzanna Czach Faculty of Medicine, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland https://orcid.org/0009-0009-6154-8022

DOI:

https://doi.org/10.12775/JEHS.2024.66.003

Keywords

Selective Serotonin Reuptake Inhibitors, Depression, Heart Failure, Endothelial Dysfunction, Drug Interactions

Abstract

This narrative review critically examines the utilization of Selective Serotonin Reuptake Inhibitors (SSRIs) in managing coexisting depression and heart failure (HF), integrating findings from various studies, clinical trials, and observational data. SSRIs, pivotal in treating mood and anxiety disorders by elevating synaptic serotonin levels, have been observed to potentially impact cardiovascular health. Specifically, SSRIs like sertraline show promise in enhancing endothelial function and exerting anti-inflammatory effects, which are beneficial in conditions like HF with preserved ejection fraction (HFpEF). Furthermore, SSRIs demonstrate favorable outcomes in reducing platelet aggregation and modulating the renin-angiotensin-aldosterone system (RAAS), suggesting a multifaceted role in HF management. However, their safety profile, particularly concerning bleeding risks, QTc prolongation, and drug interactions, necessitates careful consideration. Despite theoretical and molecular evidence supporting SSRIs' beneficial effects in HF, clinical data remain inconclusive, highlighting the need for further research. This review aims to provide a comprehensive understanding of SSRIs' effectiveness, safety, and potential benefits in treating depression and HF, offering insights for evidence-based decision-making and future research directions.

References

Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. Feb 2003;27(1):85-102. doi:10.1016/s0278-5846(02)00338-x

Harmer CJ, Cowen PJ. 'It's the way that you look at it'--a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci. 2013;368(1615):20120407. doi:10.1098/rstb.2012.0407

Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. Aug 1 2013;45:54-63. doi:10.1016/j.pnpbp.2013.04.009

Angermann CE, Gelbrich G, Stork S, et al. Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF). Eur J Heart Fail. Dec 2007;9(12):1212-22. doi:10.1016/j.ejheart.2007.10.005

Strait JB, Lakatta EG. Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail Clin. Jan 2012;8(1):143-64. doi:10.1016/j.hfc.2011.08.011

Grippo AJ, Johnson AK. Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev. Dec 2002;26(8):941-62. doi:10.1016/s0149-7634(03)00003-4

Casagrande Tango R. Psychiatric side effects of medications prescribed in internal medicine. Dialogues Clin Neurosci. Jun 2003;5(2):155-65. doi:10.31887/DCNS.2003.5.2/rcasagrandetango

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. Oct 15 2013;128(16):1810-52. doi:10.1161/CIR.0b013e31829e8807

Zuchi C, Tritto I, Carluccio E, Mattei C, Cattadori G, Ambrosio G. Role of endothelial dysfunction in heart failure. Heart Fail Rev. Jan 2020;25(1):21-30. doi:10.1007/s10741-019-09881-3

Delialis D, Mavraganis G, Dimoula A, et al. A systematic review and meta-analysis on the effect of selective serotonin reuptake inhibitors on endothelial function. J Affect Disord. Nov 1 2022;316:71-75. doi:10.1016/j.jad.2022.08.007

Thijssen DHJ, Bruno RM, van Mil A, et al. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur Heart J. Aug 7 2019;40(30):2534-2547. doi:10.1093/eurheartj/ehz350

Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. Aug 26 2003;108(8):939-44. doi:10.1161/01.CIR.0000085163.21752.0A

Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. Jul 23 2013;62(4):263-71. doi:10.1016/j.jacc.2013.02.092

van Melle JP, Buikema H, van den Berg MP, et al. Sertraline causes strong coronary vasodilation: possible relevance for cardioprotection by selective serotonin reuptake inhibitors. Cardiovasc Drugs Ther. Nov 2004;18(6):441-7. doi:10.1007/s10557-004-6221-3

Marchant DJ, Boyd JH, Lin DC, Granville DJ, Garmaroudi FS, McManus BM. Inflammation in myocardial diseases. Circ Res. Jan 6 2012;110(1):126-44. doi:10.1161/CIRCRESAHA.111.243170

Oikonomou E, Tousoulis D, Siasos G, Zaromitidou M, Papavassiliou AG, Stefanadis C. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol. Jan-Feb 2011;52(1):30-40.

Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. Mar 2012;26(3):469-79. doi:10.1016/j.bbi.2011.12.011

Lu Y, Xu X, Jiang T, et al. Sertraline ameliorates inflammation in CUMS mice and inhibits TNF-alpha-induced inflammation in microglia cells. Int Immunopharmacol. Feb 2019;67:119-128. doi:10.1016/j.intimp.2018.12.011

Taler M, Gil-Ad I, Korob I, Weizman A. The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neuroimmunomodulation. 2011;18(2):117-22. doi:10.1159/000321634

Tavakoli Ardakani M, Mehrpooya M, Mehdizadeh M, Beiraghi N, Hajifathali A, Kazemi MH. Sertraline treatment decreased the serum levels of interleukin-6 and high-sensitivity C-reactive protein in hematopoietic stem cell transplantation patients with depression; a randomized double-blind, placebo-controlled clinical trial. Bone Marrow Transplant. Apr 2020;55(4):830-832. doi:10.1038/s41409-019-0623-0

Momot K, Krauz K, Czarzasta K, Zarebinski M, Puchalska L, Wojciechowska M. Evaluation of Nitrosative/Oxidative Stress and Inflammation in Heart Failure with Preserved and Reduced Ejection Fraction. Int J Mol Sci. Nov 3 2023;24(21)doi:10.3390/ijms242115944

Munoz-Castaneda JR, Montilla P, Padillo FJ, et al. Role of serotonin in cerebral oxidative stress in rats. Acta Neurobiol Exp (Wars). 2006;66(1):1-6. doi:10.55782/ane-2006-1581

Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 2003;8(6):365-70. doi:10.1179/135100003225003393

Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. Mar 1 2000;35(3):569-82. doi:10.1016/s0735-1097(99)00630-0

Hullmann J, Traynham CJ, Coleman RC, Koch WJ. The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development. Pharmacol Res. Aug 2016;110:52-64. doi:10.1016/j.phrs.2016.05.008

Schumacher SM, Gao E, Zhu W, et al. Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. Sci Transl Med. Mar 4 2015;7(277):277ra31. doi:10.1126/scitranslmed.aaa0154

De Gobbi JI, Omoto AC, Siqueira TF, Matsubara LS, Roscani MG, Matsubara BB. Antidepressant treatment decreases daily salt intake and prevents heart dysfunction following subchronic aortic regurgitation in rats. Physiol Behav. May 15 2015;144:124-8. doi:10.1016/j.physbeh.2015.02.037

de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. May 1 2011;28(5):345-67. doi:10.2165/11589340-000000000-00000

Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. Jan 2004;91(1):119-28. doi:10.1160/TH03-05-0330

Grosman-Rimon L, Billia F, Wright E, et al. Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. Heart Fail Rev. Sep 2020;25(5):685-701. doi:10.1007/s10741-019-09860-8

Vian J, Pereira C, Chavarria V, et al. The renin-angiotensin system: a possible new target for depression. BMC Med. Aug 1 2017;15(1):144. doi:10.1186/s12916-017-0916-3

Murck H, Schussler P, Steiger A. Renin-angiotensin-aldosterone system: the forgotten stress hormone system: relationship to depression and sleep. Pharmacopsychiatry. May 2012;45(3):83-95. doi:10.1055/s-0031-1291346

Jiang W, Kuchibhatla M, Cuffe MS, et al. Prognostic value of anxiety and depression in patients with chronic heart failure. Circulation. Nov 30 2004;110(22):3452-6. doi:10.1161/01.CIR.0000148138.25157.F9

Drohomirecka A, Jankowska EA, Banasiak W, Ponikowski P. [Depression in patients with chronic heart failure]. Kardiol Pol. Dec 2008;66(12):1325-32. Depresja u chorych z niewydolnoscia serca.

Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and Anxiety in Heart Failure: A Review. Harv Rev Psychiatry. Jul/Aug 2018;26(4):175-184. doi:10.1097/HRP.0000000000000162

Fernandes N, Prada L, Rosa MM, et al. The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis. Clin Res Cardiol. Feb 2021;110(2):183-193. doi:10.1007/s00392-020-01697-8

Smolderen KG, Buchanan DM, Gosch K, et al. Depression Treatment and 1-Year Mortality After Acute Myocardial Infarction: Insights From the TRIUMPH Registry (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status). Circulation. May 2 2017;135(18):1681-1689. doi:10.1161/CIRCULATIONAHA.116.025140

Hedrick R, Korouri S, Tadros E, et al. The impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in heart failure: a systematic review. Drugs Context. 2020;9doi:10.7573/dic.2020-5-4

He W, Zhou Y, Ma J, Wei B, Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev. Nov 2020;25(6):919-926. doi:10.1007/s10741-019-09850-w

Angermann CE, Gelbrich G, Stork S, et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA. Jun 28 2016;315(24):2683-93. doi:10.1001/jama.2016.7635

Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. Jul 2003;18(4):211-7. doi:10.1097/00004850-200307000-00003

Alvarez W, Jr., Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy. Jun 2003;23(6):754-71. doi:10.1592/phco.23.6.754.32185

Andrade C, Kumar CB, Surya S. Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure. Int Clin Psychopharmacol. May 2013;28(3):145-55. doi:10.1097/YIC.0b013e32835d735d

Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med. Feb 2006;119(2):113-6. doi:10.1016/j.amjmed.2005.03.044

Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. May 2014;75(5):e441-9. doi:10.4088/JCP.13r08672

Sulej L, Momot K, Zarębiński M, Wojciechowska M. Reperfusion arrhythmias – Underestimated cause of sudden cardiac death? Medical Hypotheses. 2023;174. doi:10.1016/j.mehy.2023.111060

Downloads

  • PDF

Published

2024-04-18

How to Cite

1.
BACHURSKA, Dominika, MAREK, Jakub, GRYGORCZUK, Oliwia and CZACH, Zuzanna. The Treatment of Depression in Patients with Heart Failure. Journal of Education, Health and Sport. Online. 18 April 2024. Vol. 66, p. 50064. [Accessed 28 June 2025]. DOI 10.12775/JEHS.2024.66.003.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 66 (2024)

Section

Health Sciences

License

Copyright (c) 2024 Dominika Bachurska, Jakub Marek, Oliwia Grygorczuk, Zuzanna Czach

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 455
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

Selective Serotonin Reuptake Inhibitors, Depression, Heart Failure, Endothelial Dysfunction, Drug Interactions
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop